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Introduction
Rheumatoid arthritis (RA) patients experience a markedly
increased frequency of cardiovascular disease (CVD) as
compared with osteoarthritis (OA) patients and the
general population [1–3]. The mortality rate from CVD is
also increased in RA patients [2–4].
Adequate cardiovascular risk assessment comprises both
determination of the low-density lipoprotein (LDL) cholesterol
target in the individual patient as well as identification of the
metabolic syndrome, a cluster of cardiovascular risk factors
[5]. LDL cholesterol concentrations were found to be similar
in inflammatory arthritis (IA) patients as compared with age-
matched, sex-matched and race-matched controls [6].
Other workers, besides us, have previously documented
the presence of insulin resistance in IA [6,7]. Insulin resis-
tance is the key defect in the metabolic syndrome [8,9]. In
patients with IA, insulin resistance is associated with
obesity, inflammation, low HDL cholesterol and high
triglycerides [8–10]. These relationships reflect patho-
physiological interactions [8–10]. The use of the IS
1
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Abstract
Rheumatoid arthritis (RA) patients experience a markedly
increased frequency of cardiovascular disease. We evaluated
cardiovascular risk profiles in 79 RA patients and in 39 age-
matched and sex-matched osteoarthritis (OA) patients.
Laboratory tests comprised ultrasensitive C-reactive protein
(CRP) and fasting lipids. Insulin sensitivity (IS) was determined
by the Quantitative Insulin Sensitivity Check Index (QUICKI) in
all OA patients and in 39 of the RA patients. Ten RA patients
were on glucocorticoids. RA patients exercised more
frequently than OA patients (χ2 = 3.9, P < 0.05). Nine RA
patients and one OA patient had diabetes (χ2 = 4.5,
P < 0.05). The median CRP, the mean QUICKI and the mean
high-density lipoprotein (HDL) cholesterol were 9 mg/l (range,
0.5–395 mg/l), 0.344 (95% confidence interval [CI],
0.332–0.355) and 1.40 mmol/l (95% CI, 1.30–1.49 mmol/l) in
RA patients, respectively, as compared with 2.7 mg/l (range,
0.3–15.9 mg/l), 0.369 (95% CI, 0.356–0.383) and
1.68 mmol/l (95% CI, 1.50–1.85 mmol/l) in OA patients. Each
of these differences was significant (P < 0.05). After
controlling for the CRP, the QUICKI was similar in RA and OA
patients (P = 0.07), while the differences in HDL cholesterol
were attenuated but still significant (P = 0.03). The CRP
correlated with IS, while IS was associated with high HDL
cholesterol and low triglycerides in RA patients and not in OA
patients. A high CRP (≥8 mg/l) was associated with
hypertension (χ2 = 7.4,  P < 0.05) in RA patients. RA
glucocorticoid and nonglucocorticoid users did not differ in IS
and lipids (P > 0.05). Excess cardiovascular risk in RA
patients as compared with OA patients includes the presence
of decreased IS and HDL cholesterol in RA patients. The latter
is only partially attributable to the acute phase response. The
CRP, IS, HDL cholesterol, triglycerides and hypertension are
inter-related in RA patients, whereas none of these
relationships were found in OA patients.
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enhancing agents, namely thiazolidinediones, results in an
increase in HDL cholesterol and in a reduction in triglyc-
erides [9].
In the present study, we assessed cardiovascular risk pro-
files comprehensively in RA patients and in OA patients to
test two hypotheses. First, that RA patients experience
excess cardiovascular risk as compared with OA patients.
Second, that cardiovascular risk factors in RA patients
cluster as reported in the metabolic syndrome.
Materials and methods
Patients and investigations
Seventy-nine consecutive patients (66 women, 13 men;
69 Caucasian, 10 Asian), meeting the American College
of Rheumatology criteria for classification of RA [11], were
enrolled from our outpatient clinic. Their mean age and
disease duration were 52 years (95% CI, 49–55 years)
and 8.5 years (95% CI, 6.6–10.4 years), respectively.
Thirty-nine age-matched (mean, 56 years; 95% CI,
52–59 years), sex-matched (33 women, 6 men) and race-
matched (35 Caucasian, 4 Asian) consecutive OA
patients [12], from our outpatient clinic, also participated.
Patients on lipid-lowering agents were excluded. None of
the patients were following dietary advice at the time of
the study. We recorded the medication taken at the time
of the study, the quantities of alcohol and cigarettes con-
sumed daily, the number of hours they exercised per week,
and their family history for premature coronary heart
disease (CHD) (in male and female first-degree relatives
aged <55 and <65 years, respectively). Their body mass
index (kg/m2) was calculated, and the waist circumference
(cm) measured at the umbilical level. Patients with a blood
pressure >140/90 mmHg (measured on three occasions)
in the sitting position or on antihypertensive agents were
considered hypertensive.
Fasting blood samples (between 08:00 and 10:00 hours)
were taken in all patients for determination of the ultrasensi-
tive CRP (Tina’ quant C-reactive protein latex particle
enhanced immunoturbidimetric assay on a Hitachi 917;
Roche Diagnostics, Rotkreuz, Switzerland), of total choles-
terol, HDL cholesterol and triglycerides (Olympus Diagnos-
tics, County Clare, Ireland), of LDL cholesterol (Randox
Laboratories Ltd., Crumlin, UK), and of plasma glucose.
Fasting serum insulin (Abbott, Chicago, IL, USA) was deter-
mined in all 39 OA patients and in the last 39 of the 79 con-
secutive RA patients (33 women, 6 men; 34 Caucasian, 5
Asian; median age, 49 years [95% CI, 45–53 years]). Labo-
ratory testing was carried out using autoanalyzers, enzy-
matic methods (for lipids) and a microparticle enzyme
immunoassay on the Axsym system (for insulin).
The intra-assay and interassay coefficients of variance for
CRP and insulin were 0.43% and 1.34%, and 1.9% and
1.2%, respectively. The IS was estimated using the
QUICKI using the formula: 1 / log insulin (uU/ml) × log
glucose (mg/dl) [13]. The one patient who was using
insulin was excluded from this part of the study. In accor-
dance with our findings in a recent study on healthy volun-
teers investigated by the same laboratory [6], we used a
threshold QUICKI value of 0.337 for identification of
decreased IS.
Statistical analyses
Statistical analyses were performed by Student t tests for
comparisons of means, linear regression analyses, chi-
square tests and analyses of covariance, as appropriate.
Clustering of the metabolic syndrome features was evalu-
ated using the paradigm proposed by Timar et al. [8],
Fonseca [9] and Nishimura and Murayama [10], in which
decreased IS is associated with obesity, inflammation, low
HDL cholesterol and high triglycerides.
The respective associations were evaluated by simple
linear regression analyses (the dependent variable was the
QUICKI) since significant colinearity between variables
(e.g. HDL cholesterol correlated with triglycerides
[R2 = 0.223,  P = 0.002], and CRP correlated with HDL
cholesterol [R2 = –0.057,  P = 0.034]) precluded evalua-
tion by multiple regression analysis.
Results were expressed as the mean (95% CI) except for
prednisone doses, which were expressed as the median
(range). Since the distribution of CRP was not normal, the
respective results were also expressed as the median
(range). The CRP concentrations in OA patients versus
RA patients were compared using the Mann–Whitney U
test.
Results
Medications taken by OA patients and by RA patients
Medications taken by OA patients and RA patients (all 79
RA patients, as well as the subgroup of 39 in whom the
QUICKI was determined) are presented in Table 1. Many
of the patients were seen for the first time at our clinic,
thereby explaining why only 42 (53%) of the RA cases
were on disease-modifying agents (DMARDs). Patients on
DMARDs (data not shown) and/or glucocorticoids had
similar (P > 0.05) QUICKI and lipid values as compared to
those not on the respective agents (see later).
Cardiovascular risk factors that were similar in
frequency or extent in OA patients and in RA patients
Cardiovascular risk factors that were similar in frequency
or extent in OA patients and in RA patients are presented
in Table 2. The subgroup of 39 RA patients in whom IS
was determined was representative of all 79 RA patients.
Apart from similar frequencies in alcohol usage and
smoking in OA patients and RA patients, the number of
units of alcohol taken per week and cigarettes smoked perPage 3 of 6
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day were not different between the two diseases
(P > 0.05) (data not shown). The mean body mass index
was in the overweight range in both diseases.
Cardiovascular risk factors that differed in frequency or
extent between OA patients and RA patients
Cardiovascular risk factors that differed in frequency or
extent between OA patients and RA patients are pre-
sented in Table 3. The subgroup of 39 RA patients in
whom the QUICKI was determined was representative of
all 79 RA patients. The number of hours exercised per
week did not differ in OA exercising cases and RA exer-
cising cases (P > 0.05).
The QUICKI, total cholesterol, LDL cholesterol, HDL
cholesterol and triglycerides were 0.349 (95% CI,
0.327–0.370), 4.89 mmol/l (95% CI, 4.09–5.68 mmol/l),
2.73 mmol/l (95% CI, 2.11–3.34 mmol/l), 1.52 mmol/l
(95% CI, 1.16–1.88 mmol/l) and 1.26 mmol/l (95% CI,
0.95–1.57 mmol/l) in the glucocorticoid users, respec-
tively, and were 0.343 (95% CI, 0.330–0.356),
5.63 mmol/l (95% CI, 5.37–5.90 mmol/l), 3.41 mmol/l
(95% CI, 3.16–3.65 mmol/l), 1.37 mmol/l (95% CI,
1.26–1.48 mmol/l) and 1.68 mmol/l (95% CI, 1.43–1.94
mmol/l) in the nonglucocorticoid users. In RA patients, glu-
cocorticoid and nonglucocorticoid users had similar IS
and lipids (P > 0.05).
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Table 1
Medications taken by osteoarthritis (OA) patients (n = 39), by
all rheumatoid arthritis (RA) patients (n = 79) and by RA
patients in whom insulin sensitivity was determined (n = 39)
Medication OA (n = 39) RA (n = 79) RA (n = 39)
Antihypertensives 10 (26) 18 (23) 8 (21)
Estrogen 6 (15) 6 (8) 2 (5)
NSAID 14 (36) 33 (42) 17 (44)
Low efficacy opioids 3 (8) 5 (6) 2 (5)
Paracetamol 3 (8) 4 (5) 3 (8)
Thyroxine 2 (5) 2 (3) 0 (0)
Glucosamine 2 (5) 3 (4) 0 (0)
Omeprazole 1 (3) 0 (0) 0 (0)
DMARD 0 (0) 42 (53)* 19 (49)
Prednisone 0 (0) 10 (13)** 6 (15)
Amitryptiline 0 (0) 2 (3) 0 (0)
Zopiclone 0 (0) 3 (4) 0 (0)
Metformin 0 (0) 1 (1) 0 (0)
Gliclazide 0 (0) 3 (4) 2 (5)
Insulin 0 (0) 1 (1) 0 (0)
Fluoxetine 0 (0) 1 (1) 1 (3)
Clonazepam 0 (0) 3 (4) 0 (0)
Data presented as n (%). NSAID, nonsteroidal anti-inflammatory
agents; DMARD, disease-modifying agents. * Agents were
methotrexate (n = 37), chloroquine (n = 17), minocyclin (n = 6),
sulphasalazine (n = 4), azathioprine (n = 4), and myocrysin (n = 2). 
** Median dose was 5 mg daily (range, 3–20 mg).
Table 2
Cardiovascular risk factors that were similar (P > 0.05) in
frequency or extent in osteoarthritis (OA) patients (n = 39), in
all rheumatoid arthritis (RA) patients (n = 79) and in RA
patients in whom insulin sensitivity was determined (n = 39)
Risk factor OA (n = 39) RA (n = 79) RA (n = 39)
Smoking 10 (26) 18 (23) 12 (31)
Alcohol 20 (51) 25 (32) 13 (33)
Family history for CHD 10 (26) 29 (37) 20 (51)
Estrogen usage 6 (15) 6 (8) 2 (5)
Hypertension 23 (59) 39 (50) 20 (51)
Body mass index  26.4  26.9  25.3 
(kg/m2) (25.0–27.8) (25.6–28.2) (23.7–26.8)
Waist (cm) 91.6  90.5  93.5 
(88.0–95.3) (87.3–93.7) (88.7–98.2)
Total cholesterol  5.72  5.58  5.69 
(mmol/l) (5.34–6.10) (5.33–5.84) (5.35–6.03)
LDL cholesterol  3.32  3.34  3.5 
(mmol/l) (3.10–3.55) (3.00–3.69) (3.2–3.8)
Triglycerides 1.71  1.63  1.66 
(mmol/l) (1.25–1.96) (1.40–1.86) (1.28–2.05)
Data presented as n (%) or as mean (95% confidence interval). 
CHD, coronary heart disease; LDL, low-density lipoprotein.
Table 3
Cardiovascular risk factors that differed (P < 0.05) in frequency
or extent between osteoarthritis (OA) patients (n = 39) as
compared with all rheumatoid arthritis (RA) patients (n = 79)
and RA patients in whom insulin sensitivity was determined
(n = 39)
Risk factor OA (n = 39) RA (n = 79) RA (n = 39)
Exercisea 13 (33) 42 (53) 18 (46)
Diabetesa 1 (3) 9 (11) 4 (10)
QUICKIb 0.369 N/A 0.344 
(0.356–0.383) (0.332–0.355)
HDL cholesterol  1.68  1.40  1.40 
(mmol/l)b (1.50–1.85) (1.30–1.49) (1.30–1.50)
C-reactive protein 2.7  9  10
(mg/l)c (0.3–15.9) (0.5–395) (0.5–146)
QUICKI, Quantitative Insulin Sensitivity Check Index; HDL, high-density
lipoprotein. aData presented as n (%). bData presented as mean (95%
confidence interval). cData presented as median (range).One RA patient had type 1 diabetes. The OA patient and
two of the RA diabetic patients were not on medication for
diabetes. The onset of diabetes had not been precipitated
by the use of glucocorticoids in any of the patients, and at
the time of the study none of the diabetic patients were
taking glucocorticoids. The IS was below normal in 11
(28%) OA patients and in 16 (41%) RA patients
(χ2 = 2.04, P > 0.05), and decreased HDL cholesterol con-
centrations were found in six (15%) OA patients and in 32
(40%) RA patients (χ2 = 28.1, P < 0.001), respectively.
IS and HDL cholesterol in OA patients versus RA
patients after controlling for differences in CRP
As in our previous study [6], the acute phase response
was associated with decreased IS (R2 = –0.147,
P = 0.016) and low HDL cholesterol (R2 = –0.057,
P = 0.034). After controlling for CRP, the QUICKI was no
longer different (P = 0.07) but the HDL cholesterol
remained lower (P = 0.03) in RA patients as compared
with OA patients.
Relationships among waist circumference, CRP,
QUICKI, HDL cholesterol and triglycerides in OA
patients and RA patients
The relationships among waist circumference, CRP,
QUICKI, HDL cholesterol and triglycerides in OA patients
and RA patients are presented in Fig. 1. In OA patients,
the waist circumference contributed to the variance of the
QUICKI while the CRP did not. Also, the QUICKI was not
significantly associated with HDL cholesterol and triglyc-
eride concentrations in OA patients.
By contrast, in RA patients the CRP similarly contributed
to the variance of IS, and the latter was associated with
both HDL cholesterol and triglyceride concentrations.
Also, 27 (59%) RA patients with a CRP ≥8 mg/l (n = 46)
were hypertensive, as compared with only 10 (30%) RA
patients with a CRP <8 mg/l (n = 33). A high CRP was
associated with the presence of hypertension (χ2 = 7.4,
P < 0.05) in RA patients. The CRP was ≥8 mg/l in only
three (8%) OA patients.
Discussion
A CHD prevalence rate of 49% in RA patients as com-
pared with 27% in OA patients [1] and a fourfold
increased incidence of cardiovascular events in RA
patients as compared with the general population [2] were
recently reported. Raised total cholesterol and other tradi-
tional cardiovascular risk factors did not account for the
respective findings [2]. RA patients also experience a 1.3-
fold to 2.4-fold increased mortality rate from CHD [4].
In the present study, cardiovascular risk assessment
revealed that RA patients exercised more frequently, but
they had diabetes more often and their IS and HDL
cholesterol concentrations were lower, as compared with
OA patients. As expected, the CRP levels were also
higher in RA patients as compared with OA patients.
Inflammation, as reflected by the acute phase response, is
implicated in CVD in its own right both in the general
population [14] and in RA patients [15]. CRP may also
directly contribute to atherosclerosis. CRP is localized in
atheromatous lesions and stimulates macrophages to
produce tissue factor, an important procoagulant found in
atherosclerotic plaques [2]. In the present study, the CRP
was also significantly associated with decreased IS and
HDL cholesterol concentrations. Although elevated CRP
levels could explain the difference in IS between RA
patients and OA patients, they could only partially account
for the low HDL cholesterol concentrations.
These findings confirm our previous study [6], suggest
that RA may select for subjects with low HDL cholesterol,
and suggest that RA and CVD may share a common pre-
disposition as previously reported [6,16,17]. Further
genetic linkage studies may be worthwhile to confirm
whether HDL cholesterol concentrations are intrinsically
low in RA patients.
Both determination of the LDL cholesterol target in the
individual patient as well as identification of metabolic syn-
drome features, particularly comprising the presence of
abdominal obesity, low HDL cholesterol, elevated trigly-
cerides and plasma glucose, and hypertension, are recom-
mended in cardiovascular risk assessment [5]. Insulin
resistance constitutes an established pivotal pathogenetic
mechanism in the metabolic syndrome [8–10,18].
Although OA is associated with insulin resistance [19]
and dyslipidemia [19,20], both IS and HDL cholesterol
Arthritis Research    Vol 4 No 5 Dessein et al.
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Figure 1
Relationships among waist circumference, C-reactive protein,
Quantitative Insulin Sensitivity Check Index (QUICKI), high-density
lipoprotein cholesterol (HDL chol) and triglycerides in osteoarthritis
patients (n = 39) and rheumatoid arthritis patients (n = 39). Significant
associations are printed in bold italic.concentrations were still significantly lower in RA patients
as compared with OA patients. Also, eight RA patients
and one OA patient had type 2 diabetes. In a recent study,
diabetes was identified in 38 out of 236 (16.1%) RA
patients, as compared with 442 out of 4635 (9.5%) non-
RA subjects (P ≤ 0.0001) [2]. Also, type 2 diabetes is a
late complication of the metabolic syndrome [8,9] and its
occurrence in our patients was not related to the use of
glucocorticoids. The high frequency of diabetes in the
present RA cohort may not be a chance finding.
In view of the high prevalence of insulin resistance in IA
[6], the pathogenetic role of insulin resistance in the meta-
bolic syndrome and its relationship to the acute phase
response in IA [6], we analyzed the relationships among
abdominal obesity, CRP, IS, HDL cholesterol and trigly-
cerides in both OA patients and RA patients. In OA
patients, the waist circumference contributed to the vari-
ance in IS but no other associations could be identified.
By contrast, in RA patients, all of the respective risk
factors were interdependent. Also, a high CRP was asso-
ciated with the presence of hypertension.
In the present study, we found inflammation and abdomi-
nal obesity to be associated with decreased IS in RA
patients. Insulin resistance and the other metabolic syn-
drome features also relate to psychosocial stress and
other environmental factors’ related abnormalities in corti-
sol, sex steroid and growth hormone secretion [21]. The
role of psychosocial stressors in decreased IS in RA
patients requires further study.
The biochemical disturbances clustering in the metabolic
syndrome may participate in the onset and persistence of
IA [6]. With regard to cardiovascular risk, our findings
suggest that identification of the metabolic syndrome may
be particularly important in this condition. RA patients in a
recent study were found to have high levels of small,
dense LDL particles, and this was related to the acute
phase response [22]. High circulating levels of small,
dense LDL particles constitute another characteristic
feature of the metabolic syndrome [5]. Furthermore, the
acute phase response may contribute to atherosclerosis
through endothelial activation and interaction with pro-
coagulant factors [3,23]. The high prevalence of CVD in
RA patients [1,2] also implicates that this condition should
be considered a CHD equivalent when determining the
LDL cholesterol target (i.e. the latter may be as low as 2.6
mmol/l) [5]. Indeed, mildly deranged LDL cholesterol con-
centrations, LDL/HDL ratios and triglyceride concentra-
tions mediate the accelerated atherosclerosis in RA
patients [3]. In 58 (73%) of our RA patients, the LDL
cholesterol was >2.6 mmol/l.
A limitation of the present study, as applies to other
reports on CVD in RA patients [2,3], is that most patients
were on drug treatment. Only patients on lipid-lowering
agents were excluded. However, excluding patients on
drug treatment may have yielded results that do not repre-
sent the situation in the clinic. Also, patients on glucocorti-
coids and/or DMARDs experienced no differences in IS or
lipid values as compared with those patients who were not
on these agents. Of interest, in this regard, both gluco-
corticoids and DMARDs were shown to attenuate insulin
resistance in IA, an effect that was attributed to acute
phase response suppression [24].
Conclusion
Excess cardiovascular risk in RA patients includes the
acute phase response and decreased IS and HDL choles-
terol, while the respective risk factors are closely inter-
linked in this condition. How inflammation and other
cardiovascular risk factors interact in the pathogenesis of
enhanced atherosclerosis in RA patients requires further
elucidation. In the meantime, our findings implicate the
need for evaluating cardiovascular risk profiles compre-
hensively in these patients.
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